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COST-EFFECTIVENESS ANALYSIS OF
CURRENTLY MARKETED LONG-TERM
CONTRACEPTIVES
Knight K, Reyes E,Wallace J, Chiou CF,Wade S, Borenstein J
Cedars-Sinai Health System, Zynx Health Incorporated,
Beverly Hills, CA, USA
OBJECTIVES: To compare the costs and beneﬁts, from
a health plan perspective, of contraceptive methods cur-
rently marketed in the United States among individuals
desiring long-term contraception.
METHODS: A semi-Markov model was constructed 
to compare cost-effectiveness among 14 contraceptive
strategies (including injectables, implants, oral contra-
ceptives, IUDs, barrier methods, and surgical methods).
Primary health states included method discontinuation,
initial/continued use, method failure and plan disenroll-
ment with transitions every year for ﬁve years. Costs for
method failure, other discontinuation, and method-
related events (amenorrhea, hysterectomy, menorrhagia,
urinary tract infection, and venous thromboembolism)
are included in the model. Baseline event rates, costs, and
method effects on rates were derived from a comprehen-
sive literature review, average wholesale drug prices, and
the 2000 Medicare Reimbursement Fee Schedule, in 
conjunction with expert opinion. One-way sensitivity
analyses were performed on several key variables.
RESULTS: The ﬁve most effective methods were vasec-
tomy, tubal ligation, implant, progestin-releasing IUD,
and copper IUD, with average effectiveness of (99.9%,
99.8%, 98.6%, 98.2% and 97.8%, respectively). The 
ﬁve least expensive methods were vasectomy, progestin-
releasing IUD, copper IUD, implant, and injectables 
with respective ﬁve-year costs/person of $800, $1,196,
$1,217, $1,237, and $1,764. Vasectomy dominated other
methods over ﬁve years. After excluding vasectomy, 
progestin-releasing IUD, implant and tubal ligation 
dominated, with a marginal cost-effectiveness of $71 per
additional percent of effectiveness between progestin-
releasing IUD and implant, and $958 between progestin-
releasing IUD and tubal ligation. The cost-effectiveness
ranking among methods did not vary signiﬁcantly in most
sensitivity analyses except those based on method costs.
CONCLUSIONS: Over ﬁve years, vasectomy is the most
cost-effective long-term contraceptive strategy. Among
long-term contraceptive options for women, progestin-
releasing IUD had a lower cost-effectiveness ratio than
either implant or tubal ligation and dominated all other
methods.
PMW6
COST EFFECTIVENESS MODELING COMPARING
RECOMBINANT FSH WITH URINARY FSH FOR
OVARIAN STIMULATION—A MULTINATIONAL
EVALUATION
Beresniak A1, Daya S2, Duru G3,Auray JP3
1Serono International SA, Geneva, Switzerland; 2McMaster
University, Hamilton, Ontario, Canada; 3Université Claude
Bernard Lyon,Villeurbanne, France
OBJECTIVES: The focus on cost-containment imposed
by shrinking national health care budgets is increasingly
putting pressure on investigators to demonstrate that
newer interventions are cost-effective. In assisted repro-
ductive technology (ART), a shift in usage is occurring
from urinary derived to biotechnology – derived (recom-
binant) gonadotropins for ovarian stimulation. Provision
of treatment with ART involves several cycles, each asso-
ciated with multiple steps with varying outcomes at each
step. To take into account all the situations that are pos-
sible during the repeated cycles of treatment when trying
to evaluate different ovarian stimulation regimens is a
complex task that requires large numbers of subjects to
adequately address the cost-effectiveness A more efﬁcient
approach is to employ modeling techniques that can
easily be applied to the different national health care
systems. The objective of this study was to compare the
cost-effectiveness of recombinant(r) FSH with urinary(u)
FSH in the UK, USA, Germany and Spain.
METHODS: The analyses used the Markov model and
Monte-Carlo simulations taking into account the differ-
ent health care environments in the four countries. For
each nation, costs were provided by their national for-
mulary and clinic tariff, and probabilities for outcomes
were obtained from randomized controlled trials, the
medical literature and national registries. The data were
they validated by a panel of national experts and the esti-
mation of variability in the transition probabilities was
also ratiﬁed by the panel. This approach provided a range
of transitional probabilities from which a precise stan-
dard deviation could be obtained for each outcome. The
ﬁnal Markov matrix included 300–600 health states 
that represented the complete ART process over multiple
cycles involving the transfer of fresh or cryopreserved
embryos.
RESULTS: Country Mean cost per pregnancy uFSH rFSH
Difference UK £6060 5906 154 USA $47,096 40,688
6408 Germany DM 45,510 43,311 2199 Spain PTAS
3,405,347 3,284,241 121,106
CONCLUSION: The studies conﬁrmed that rFSH is 
more cost-effective than uFSH for ovarian stimulation.
The lower average cost per pregnancy was observed con-
sistently in each country.
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IDENTIFYING PATIENT AND HOSPITAL-
RELATED PREDICTORS OF MATERNITY
LENGTH OF STAY AND TOTAL INPATIENT
CHARGES FOR OBSTETRICAL DELIVERIES IN A
NATIONAL SAMPLE
Mody R,Amonkar M, Kamat S
West Virginia University, Morgantown, WV, USA
Obstetrical delivery is the most frequent cause of 
hospital admissions (4 million) in the US.
OBJECTIVE: To assess the relationship of patient and
hospital-related characteristics with maternity length of
stay (LOS) and charges for obstetrical deliveries.
